SLRX
$0.72
Salarius Pharmaceuticals
($.01)
(1.61%)
SLRX
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  $0.00
Revenue:  $0.00 Mil
Wednesday
Nov 11
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SLRX reports earnings?
Beat
Meet
Miss

Where is SLRX's stock price going from here?
Up
Flat
Down
Stock chart of SLRX
Analysts
Summary of analysts' recommendations for SLRX
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Salarius Pharmaceuticals Inc. is a clinical-stage oncology company. It develops therapies for the treatment of cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius Pharmaceuticals Inc., formerly known as Flex Pharma Inc., is based in Houston, Texas.